Udvalget for Humanmedicinske Lægemidler (CHMP) besluttede, at fordelene ved VFEND er større end risiciene i forbindelse med behandling af alvorlige svampeinfektioner, særligt hos patienter med livstruende infektioner.
The Committee for Medicinal products for Human Use (CHMP) decided that VFEND’ s benefits are greater than its risks for treatment of serious fungal infections, especially in patients with life- threatening infection.